Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: Potential theranostic approach to cancer

Journal of Proteome Research

Volumn 6, Issue 7, 2007, Pages 2509-2517

  Philip, Ramila ^a   Murthy, Sidhartha ^a   Krakover, Jonathan ^a   Sinnathamby, Gomathinayagam ^a   Zerfass, Jennifer ^a   Keller, Lorraine ^a   Philip, Mohan ^a  

^a Immunotope Inc   (United States)

Author keywords

Autoantigens; Biomarker; Early diagnosis; Immunoproteomics; Immunotherapy; Ovarian cancer

Indexed keywords

AUTOANTIBODY; CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEOME;

AMINO ACID SEQUENCE; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CARCINOGENESIS; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; PROTEOMICS; T LYMPHOCYTE;

ADULT; AGED; AUTOANTIBODIES; AUTOANTIGENS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MASS SPECTROMETRY; MIDDLE AGED; OVARIAN NEOPLASMS; PEPTIDES; PROTEOME; PROTEOMICS; T-LYMPHOCYTES;

EID: 34547195299     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr0606777     Document Type: Article

References (76)

1. Old, L. J.; Chen, Y. T. New paths in human cancer serology. J. Exp. Med. 1998, 187 (8), 1163-7.
2. Robinson, C.; Callow, M.; Stevenson, S.; Scott, B.; Robinson, B. W.; Lake, R. A. Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am. J. Respir. Cell Mol. Biol. 2000, 22 (5), 550-6.
3. Luo, L. Y.; Herrera, I.; Soosaipillai, A.; Diamandis, E. P. Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. Br. J. Cancer 2002, 87 (3), 339-43.
4. Yamamoto, A.; Shimizu, E.; Ogura, T.; Sone, S. Detection of autoantibodies against L-myc oncogene products in sera from lung cancer patients. Int. J. Cancer 1996, 69 (4), 283-9.
5. Jager, E.; Chen, Y. T.; Drijfhout, J. W.; Karbach, J.; Ringhoffer, M.; Jager, D.; Arand, M.; Wada, H.; Noguchi, Y.; Stockert, E.; Old, L. J.; Knuth, A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 1998, 187 (2), 265-70.
6. Gure, A. O.; Altorki, N. K.; Stockert, E.; Scanlan, M. J.; Old, L. J.; Chen, Y. T. Human lung cancer antigens recognised by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. Cancer Res. 1998, 58 (5), 1034-41.
7. Peoples, G. E.; Schoof, D. D.; Andrews, J. V.; Goedegebuure, P. S.; Eberlein, T. J. T-cell recognition of ovarian cancer. Surgery 1993, 114 (2), 227-34.
8. Azuma, K.; Shichijo, S.; Maeda, Y.; Nakatsura, T.; Nonaka, Y.; Fujii, T.; Koike, K.; Itoh, K. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res. 2003, 63 (4), 854-8.
9. Dalerba, P.; Maccalli, C.; Casati, C.; Castelli, C.; Parmiani, G. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003, 46 (1), 33-57.
10. Bremers, A. J.; Andreola, S.; Leo, E.; Gallino, F.; Rini, F.; Lombardo, C.; Belli, F.; Kuppen, P. J.; Parmiani, G.; Castelli, C. T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigens. Int. J. Cancer 2000, 88 (6), 956-61.
11. Miyazono, Y.; Kamogawa, Y.; Ryo, K.; Furukawa, T.; Mitsuhashi, M.; Yamauchi, K.; Kameoka, T.; Hayashi, N. Effect of B7.1-transfected human colon cancer cells on the induction of autologous tumour-specific cytotoxic T cells. J Gastroenterol Hepatol 1999, 14 (10), 997-1003.
12. Habal, N.; Gupta, R. K.; Bilchik, A. J.; Yee, R.; Leopoldo, Z.; Ye, W.; Elashoff, R. M.; Morton, D. L. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 2001, 8 (5), 389-401.
13. Chung-Faye, G. A.; Kerr, D. J. ABC of colorectal cancer: Innovative treatment for colon cancer. Bmj 2000, 321 (7273), 1397-9.
14. Tamura, M.; Nishizaka, S.; Maeda, Y.; Ito, M.; Harashima, N.; Harada, M.; Shichijo, S.; Itoh, K. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes. Jpn. J. Cancer Res. 2001, 92 (7), 762-7.
15. Slovin, S. F.; Lackman, R. D.; Ferrone, S.; Kiely, P. E.; Mastrangelo, M. J. Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J. Immunol. 1986, 137 (9), 3042-8.
16. Schendel, D. J.; Gansbacher, B.; Oberneder, R.; Kriegmair, M.; Hofstetter, A.; Riethmuller, G.; Segurado, O. G. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J. Immunol. 1993, 151 (8), 4209-20.
17. Wolfel, T.; Herr, W.; Coulie, P.; Schmitt, U. Meyer zum Buschenfelde, K. H.; Knuth, A. Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T-lymphocyte (CTL) clones. Int. J. Cancer 1993, 54 (4), 636-44.
18. Yasumura, S.; Hirabayashi, H.; Schwartz, D. R.; Toso, J. F.; Johnson, J. T.; Herberman, R. B.; Whiteside, T. L. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res. 1993, 53 (6), 1461-8.
19. Slingluff, C. L., Jr.; Cox, A. L.; Stover, J. M., Jr.; Moore, M. M.; Hunt, D. F.; Engelhard, V. H. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res. 1994, 54 (10), 2731-7.
20. Hwu, P.; Freedman, R. S. The immunotherapy of patients with ovarian cancer. J Immunother 2002, 25 (3), 189-201.
21. Parmiani, G.; Castelli, C.; Dalerba, P.; Mortarini, R.; Rivoltini, L.; Marincola, F. M.; Anichini, A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 2002, 94 (11), 805-18.
22. Rammensee, H. G.; Friede, T.; Stevanoviic, S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995, 41 (4), 178-228.
23. Turk, M. J.; Wolchok, J. D.; Guevara-Patino, J. A.; Goldberg, S. M.; Houghton, A. N. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 2002, 188, 122-35.
24. Vijayasaradhi, S.; Bouchard, B.; Houghton, A. N. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J. Exp. Med. 1990, 171 (4), 1375-80.
25. Takechi, Y.; Hara, I.; Naftzger, C.; Xu, Y.; Houghton, A. N. A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res 1996, 2 (11), 1837-42.
26. Fernandez Madrid, F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett. 2005, 230 (2), 187-98.
27. Tomkiel, J. E.; Alansari, H.; Tang, N.; Virgin, J. B.; Yang, X.; VandeVord, P.; Karvonen, R. L.; Granda, J. L.; Kraut, M. J.; Ensley, J. F.; Fernandez-Madrid, F. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin Cancer Res 2002, 8 (3), 752-8.
28. Fernandez-Madrid, F.; Tang, N.; Alansari, H.; Granda, J. L.; Tait, L.; Amirikia, K. C.; Moroianu, M.; Wang, X.; Karvonen, R. L. Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer. Cancer Res. 2004, 64 (15), 5089-96.
29. Tan, E. M. Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J. Clin. Invest. 2001, 108 (10), 1411-5.
30. Fernandez-Madrid, F.; Karvonen, R. L.; Kraut, M. J.; Czelusniak, B.; Ager, J. W. Autoimmunity to collagen in human lung cancer. Cancer Res. 1996, 56 (1), 121-6.
31. Fernandez-Madrid, F.; VandeVord, P. J.; Yang, X.; Karvonen, R. L.; Simpson, P. M.; Kraut, M. J.; Granda, J. L.; Tomkiel, J. E. Antinuclear antibodies as potential markers of lung cancer. Clin Cancer Res 1999, 5 (6), 1393-400.
32. Wolfel, T.; Hauer, M.; Schneider, J.; Serrano, M.; Wolfel, C.; Klehmann-Hieb, E.; De Plaen, E.; Hankeln, T.; Meyer zum Buschenfelde, K. H.; Beach, D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269 (5228), 1281-4.
33. Pieper, R.; Christian, R. E.; Gonzales, M. I.; Nishimura, M. I.; Gupta, G.; Settlage, R. E.; Shabanowitz, J.; Rosenberg, S. A.; Hunt, D. F.; Topalian, S. L. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J. Exp. Med. 1999, 189 (5), 757-66.
34. Moreau-Aubry, A.; Le Guiner, S.; Labarriere, N.; Gesnel, M. C.; Jotereau, F.; Breathnach, R. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. J. Exp. Med. 2000, 191 (9), 1617-24.
35. Van Den Eynde, B. J.; Gaugler, B.; Probst-Kepper, M.; Michaux, L.; Devuyst, O.; Lorge, F.; Weynants, P.; Boon, T. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J. Exp. Med. 1999, 190 (12), 1793-800.
36. van der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; De Plaen, E.; Van den Eynde, B.; Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254 (5038), 1643-7.
37. Lucas, S.; De Plaen, E.; Boon, T. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int. J. Cancer 2000, 87 (1), 55-60.
38. Zeng, G.; Touloukian, C. E.; Wang, X.; Restifo, N. P.; Rosenberg, S. A.; Wang, R. F. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 2000, 165 (2), 1153-9.
39. Jager, E.; Jager, D.; Karbach, J.; Chen, Y. T.; Ritter, G.; Nagata, Y.; Gnjatic, S.; Stockert, E.; Arand, M.; Old, L. J.; Knuth, A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 2000, 191 (4), 625-30.
40. Chen, Y. T.; Scanlan, M. J.; Sahin, U.; Tureci, O.; Gure, A. O.; Tsang, S.; Williamson, B.; Stockert, E.; Pfreundschuh, M.; Old, L. J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (5), 1914-8.
41. Jager, E.; Stockert, E.; Zidianakis, Z.; Chen, Y. T.; Karbach, J.; Jager, D.; Arand, M.; Ritter, G.; Old, L. J.; Knuth, A. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int. J. Cancer 1999, 84 (5), 506-10.
42. Boyse, E. A. O. L. Some aspects of normal and abnormal cell surface genetics. Ann Rev Genet 1969, 3, 269-290.
43. Wang, R. F.; Wang, X.; Atwood, A. C.; Topalian, S. L.; Rosenberg, S. A. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999, 284 (5418), 1351-4.
44. Houghton, A. N.; Eisinger, M.; Albino, A. P.; Cairncross, J. G.; Old, L. J. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 1982, 156 (6), 1755-66.
45. Lloyd, K. O. Humoral immune responses to tumor-associated carbohydrate antigens. Semin Cancer Biol 1991, 2 (6), 421-31.
46. Disis, M. L.; Calenoff, E.; McLaughlin, G.; Murphy, A. E.; Chen, W.; Groner, B.; Jeschke, M.; Lydon, N.; McGlynn, E.; Livingston, R. B.; et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994, 54 (1), 16-20.
47. Barnd, D. L.; Lan, M. S.; Metzgar, R. S.; Finn, O. J. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. U.S.A. 1989, 86 (18), 7159-63.
48. Houghton, A. N.; Real, F. X.; Davis, L. J.; Cordon-Cardo, C.; Old, L. J. Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J. Exp. Med. 1987, 165 (3), 812-29.
49. Bowne, W. B.; Srinivasan, R.; Wolchok, J. D.; Hawkins, W. G.; Blachere, N. E.; Dyall, R.; Lewis, J. J.; Houghton, A. N. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 1999, 190 (11), 1717-22.
50. Weber, L. W.; Bowne, W. B.; Wolchok, J. D.; Srinivasan, R.; Qin, J.; Moroi, Y.; Clynes, R.; Song, P.; Lewis, J. J.; Houghton, A. N. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest. 1998, 102 (6), 1258-64.
51. Merimsky, O.; Shoenfeld, Y.; Chaitchik, S.; Yecheskel, G.; Fishman, P. Antigens and antibodies in malignant melanoma. Tumour Biol 1994, 15 (4), 188-202.
52. Markovic, S. N.; Suman, V. J.; Ingle, J. N.; Kaur, J. S.; Pitot, H. C.; Loprinzi, C. L.; Rao, R. D.; Creagan, E. T.; Pittelkow, M. R.; Allred, J. B.; Nevala, W. K.; Celis, E. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 2006, 29 (4), 352-60.
53. Peoples, G. E.; Goedegebuure, P. S.; Smith, R.; Linehan, D. C.; Yoshino, I.; Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. U.S.A. 1995, 92 (2), 432-6.
54. Fisk, B.; Blevins, T. L.; Wharton, J. T.; Ioannides, C. G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 1995, 181 (6), 2109-17.
55. Brossart, P.; Stuhler, G.; Flad, T.; Stevanovic, S.; Rammensee, H. G.; Kanz, L.; Brugger, W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 1998, 58 (4), 732-6.
56. Ward, R. L.; Hawkins, N. J.; Coomber, D.; Disis, M. L. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum Immunol 1999, 60 (6), 510-5.
57. Taylor, D. D.; Gercel-Taylor, C. Tumor-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? (review). Oncol Rep 1998, 5 (6), 1519-24.
58. Qin, S.; Qiu, W.; Ehrlich, J. R.; Ferdinand, A. S.; Richie, J. P.; O'Leary, M, P.; Lee, M. L.; Liu, B. C. Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 2006, 6 (10), 3199-209.
59. Wang, X.; Yu, J.; Sreekumar, A.; Varambally, S.; Shen, R.; Giacherio, D.; Mehra, R.; Montie, J. E.; Pienta, K. J.; Sanda, M. G.; Kantoff, P. W.; Rubin, M. A.; Wei, J. T.; Ghosh, D.; Chinnaiyan, A. M. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 2005, 353 (12), 1224-35.
60. Chatterjee, M.; Mohapatra, S.; Ionan, A.; Bawa, G.; Ali-Fehmi, R.; Wang, X.; Nowak, J.; Ye, B.; Nahhas, F. A.; Lu, K.; Witkin, S. S.; Fishman, D.; Munkarah, A.; Morris, R.; Levin, N. K.; Shirley, N. N.; Tromp, G.; Abrams, J.; Draghici, S.; Tainsky, M. A. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006, 66 (2), 1181-90.
61. Angelopoulou, K.; Rosen, B.; Stratis, M.; Yu, H.; Solomou, M.; Diamandis, E. P. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer 1996, 78 (10), 2146-52.
62. Wang, Y.; Han, K. J.; Pang, X. W.; Vaughan, H. A.; Qu, W.; Dong, X. Y.; Peng, J. R.; Zhao, H. T.; Rui, J. A.; Leng, X. S.; Cebon, J.; Burgess, A. W.; Chen, W. F. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J. Immunol. 2002, 169 (2), 1102-9.
63. Le Naour, F.; Brichory, F.; Misek, D. E.; Brechot, C.; Hanash, S. M.; Beretta, L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol. Cell. Proteomics 2002, 1 (3), 197-203.
64. Fossa, A.; Alsoe, L.; Crameri, R.; Funderud, S.; Gaudernack, G.; Smeland, E. B. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother 2004, 53 (5), 431-8.
65. Suzuki, H.; Akakura, K.; Igarashi, T.; Ueda, T.; Ito, H.; Watanabe, M.; Nomura, F.; Ochiai, T.; Shimada, H. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. J Urol 2004, 171 (1), 182-6.
66. Zhang, J. Y.; Casiano, C. A.; Peng, X. X.; Koziol, J. A.; Chan, E. K.; Tan, E. M. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003, 12 (2), 136-43.
67. Yoshino, I.; Goedegebuure, P. S.; Peoples, G. E.; Parikh, A. S.; DiMaio, J. M.; Lyerly, H. K.; Gazdar, A. F.; Eberlein, T. J. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res. 1994, 54 (13), 3387-90.
68. Brossart, P.; Wirths, S.; Stuhler, G.; Reichardt, V. L.; Kanz, L.; Brugger, W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000, 96 (9), 3102-8.
69. Nijman, H. W.; van Diest, P. J.; Poort-Keesom, R. J.; von Mensdorff-Pouilly, S.; Verstraeten, R. A.; Kummer, A.; Meijer, C. J.; Melief, C. J.; Hilgers, J.; Kenemans, P. T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2001, 94 (1), 114-20.
70. Bernhard, H.; Salazar, L.; Schiffman, K.; Smorlesi, A.; Schmidt, B.; Knutson, K. L.; Disis, M. L. Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer 2002, 9 (1), 33-44.
71. van Rhee, F.; Szmania, S. M.; Zhan, F.; Gupta, S. K.; Pomtree, M.; Lin, P.; Batchu, R. B.; Moreno, A.; Spagnoli, G.; Shaughnessy, J.; Tricot, G. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005, 105 (10), 3939-44.
72. Consogno, G.; Manici, S.; Facchinetti, V.; Bachi, A.; Hammer, J.; Conti-Fine, B. M.; Rugarli, C.; Traversari, C.; Protti, M. P. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 2003, 101 (3), 1038-44.
73. Mumberg, D.; Monach, P. A.; Wanderling, S.; Philip, M.; Toledano, A. Y.; Schreiber, R. D.; Schreiber, H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (15), 8633-8.
74. Pardoll, D. M., Topalian, S. L. The role of CD4 + T cell responses in antitumor immunity. Curr. Opin. Immunol. 1998, 10 (5), 588-94.
75. Toes, R. E.; Ossendorp, F.; Offringa, R.; Melief, C. J. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 1999, 189 (5), 753-6.
76. Shastri, N.; Schwab, S.; Serwold, T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 2002, 20, 463-93.